INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors
Chawla, N. S. Kuttschreuter, L. Sankhala, K. K. Benafif, S. Carter, L. Coupe, N. Evans, T. R. J. Humphries, T. G. Kao, S. C. H. Walter, H. S.
Chawla, N. S.
Kuttschreuter, L.
Sankhala, K. K.
Benafif, S.
Carter, L.
Coupe, N.
Evans, T. R. J.
Humphries, T. G.
Kao, S. C. H.
Walter, H. S.
Abstract
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Chawla NS, Kuttschreuter L, Sankhala KK, Benafif S, Carter L, Coupe N, et al. INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. 2025 JUN 1;43(16_SUPPL):TPS2683-TPS. PubMed PMID: WOS:001534377900001. English.